Experience with 274 Cardiac Transplant Recipients with Posttransplant Lymphoproliferative Disorder: A Report from the Israel Penn International Transplant Tumor Registry
- 15 December 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 78 (11), 1676-1682
- https://doi.org/10.1097/01.tp.0000144333.19106.58
Abstract
Posttransplant lymphoproliferative disorder (PTLD) is a life-threatening complication that occurs in a small but significant minority of solid organ transplant recipients. Published experiences with PTLD in cardiac transplant recipients are limited to relatively small single-center reports. This report presents experience with 274 cases of PTLD in cardiac transplant recipients reported to the Israel Penn International Transplant Tumor Registry (IPITTR). PTLD carried an ominous prognosis: Kaplan Meier survival after PTLD diagnosis was 45%, 33%, 30%, and 13%, respectively, at 1, 3, 5, and 10 years. Common causes of death included: PTLD, cardiovascular collapse, and infection; all occurred at a median of less than 6 months. Risk of death from cardiovascular collapse secondary to immunosuppression withdrawal was substantial (28%), indicating that a fine balance exists between death from PTLD and from sudden cardiac death due to acute rejection. PTLD therapy in the majority of patients consisted of combination therapy (49%). Survival in patients receiving immunosuppression minimization (ISM) alone was 32%, with ISM plus other therapy was 27%, and with other therapies not containing ISM was 11% (P PTLD in cardiac transplant recipients is associated with low long-term survival rates. Analysis of PTLD therapies and outcomes suggest that immunosuppression minimization, when applied, improves survival. However, risk of sudden death may mitigate the positive effect of ISM. This observation has important implications for ISM in PTLD therapy in cardiac transplant recipients. Carefully designed prospective studies are needed to evaluate the positive and negative effects of ISM in cardiac transplant recipients with PTLD.Keywords
This publication has 10 references indexed in Scilit:
- TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE WITH RITUXIMABTransplantation, 2002
- Treatment of post-transplant lymphoproliferative disorder with monoclonal cd20 antibody (rituximab) after heart transplantationThe Journal of Heart and Lung Transplantation, 2001
- Posttransplantation lymphoproliferative disease in heart and heart-lung transplant recipients: thirty years experience at our hospital.The Journal of Heart and Lung Transplantation, 2001
- Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patientsAnnals Of Oncology, 2000
- The biology of Epstein–Barr virus in post‐transplant lymphoproliferative diseaseTransplant Infectious Disease, 1999
- Malignancies complicating organ transplantationTransplantation Proceedings, 1998
- Management of lymphoproliferative disorders after cardiac transplantationThe Annals of Thoracic Surgery, 1993
- Lymphoproliferative disorder early after cardiac transplantationThe American Journal of Cardiology, 1991
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1990
- LYMPHOMA IN CARDIAC ALLOTRANSPLANT RECIPIENTSTransplantation, 1982